Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C

@article{Bitetto2011VitaminDS,
  title={Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C},
  author={Davide Bitetto and Carlo Fabris and Ezio Fornasiere and Corrado Pipan and Elisa Fumolo and Annarosa Cussigh and Sara Bignulin and Sara Cmet and Elisabetta Fontanini and Edmondo Falleti and Romina Martinella and Mario Pirisi and Pierluigi Toniutto},
  journal={Transplant International},
  year={2011},
  volume={24}
}
In immune‐competent patients, higher vitamin D levels predicted sustained viral response (SVR) following interferon (INF) and ribavirin therapy for chronic hepatitis C. This study aimed to verify the influence of vitamin D serum levels and/or vitamin D supplementation in predicting SVR rates for recurrent hepatitis C (RHC). Forty‐two consecutive patients were treated for RHC with combination therapy with INF‐α and ribavirin for 48 weeks. Vitamin D serum levels were measured in all patients… 
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.
TLDR
Adding vitamin D to conventional Peg-α-2b/ribavirin therapy for treatment-naïve patients with chronic HCV genotype 1 infection significantly improves the viral response.
Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
  • G. Esmat, M. El Raziky, W. Doss
  • Medicine
    Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
  • 2015
TLDR
Despite its role in other genotypes, vitamin D supplementation has no significant impact on SVR in HCV Genotype 4 patient and no correlation was found between vitamin D levels and stage of liver fibrosis.
25-Vitamin D levels in chronic hepatitis C infection: association with cirrhosis and sustained virologic response
TLDR
The prevalence of vitamin D deficiency is higher in hepatitis-C–related cirrhotic cohorts compared to non-cirrhotic patients and correlates with components of hepatic function, but neither pretreatment vitamin D level nor the change during therapy was associated with an increased rate of sustained virologic response.
Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.
TLDR
Low vitamin D levels predicts negative treatment outcome, and adding vitamin D to conventional Peg/RBV therapy for patients with HCV genotype 2-3 significantly improves viral response.
Vitamin D status and viral response to therapy in hepatitis C infected children.
TLDR
Adding vitamin D to conventional Peg/RBV therapy significantly improved the virological response and helped to prevent the risk of emerging bone fragility.
25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients
TLDR
25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients, as measured at baseline in frozen serum.
Vitamin D status and viral response to therapy in hepatitis C infected children Prospective Study
TLDR
Adding vitamin D to conventional Peg/ RBV therapy significantly improved the virological response and helped to prevent the risk of emerging bone fragility.
Does Vitamin D Level Affect the Response to Antiviral Treatment in Egyptian Patients with Chronic Hepatitis C
TLDR
Vitamin D levels could affect liver necro-inflammatory process in Egyptian patients with chronic hepatitis C infection, but did not show significant effect on response to antiviral therapy.
Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials
TLDR
Higher vitamin D status was not beneficially associated with responses to therapy; if anything, patients with higher vitamin D concentrations were less likely to attain SVR and the data do not support a role for vitamin D supplementation as an adjuvant therapy for HCV.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C
TLDR
Low vitamin D is linked to severe fibrosis and low SVR on interferon (IFN)‐based therapy and G1 CHC patients had low 25(OH)D serum levels, possibly because of reduced CYP27A1 expression.
Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial
TLDR
In patients with chronic hepatitis C; combined interferon and cyclosporin A treatment was more effective thanInterferon monotherapy, mostly achieved in patients with a high viral load and HCV genotype 1.
Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.
TLDR
In patients with chronic hepatitis C; combined interferon and cyclosporin A treatment was more effective thanInterferon monotherapy, and the benefit was mostly achieved in patients with a high viral load and HCV genotype 1.
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
TLDR
The combination of interferon alfa-2b plus ribavirin induced a sustained virologic response in 21% of transplant recipients with recurrent hepatitis C, however, 43% discontinued therapy due to adverse events (primarily severe anemia).
An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection
TLDR
IFN therapy in liver transplant recipients with chronic active hepatitis caused by hepatitis C virus has poor antiviral effect and can induce chronic rejection, and its use in this setting should be cautious.
Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C
  • M. Berenguer, A. Palau, J. Berenguer
  • Medicine
    Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • 2006
TLDR
In conclusion, the efficacy of pegIFN‐Rbvr is similar to the non‐transplant population, and an EVR at 3 months is useful to predict lack of response.
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
TLDR
In a sizeable proportion of patients with advanced HCV, LADR may render blood free of HCV RNA, stabilize clinical course, and prevent posttransplantation recurrence.
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
TLDR
It is demonstrated that in liver transplantation recipients, antiviral therapy slows disease progression (particularly in sustained virological responders), as shown by its effects on liver histology and on HVPG.
...
1
2
3
4
5
...